Prevalence, predictors, and outcomes of pulmonary hypertension in CKD
Journal of the American Society of Nephrology, ISSN: 1533-3450, Vol: 27, Issue: 3, Page: 877-886
2016
- 81Citations
- 34Usage
- 107Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations81
- Citation Indexes80
- 80
- CrossRef54
- Policy Citations1
- Policy Citation1
- Usage34
- Abstract Views34
- Captures107
- Readers107
- 107
Article Description
Pulmonary hypertension (PH) is associated with poor outcomes in the dialysis and general populations, but its effect in CKDis unclear.We evaluated the prevalence and predictors of PH measures and their associationswith long-term clinical outcomes in patients with nondialysis-dependent CKD. Chronic Renal Insufficiency Cohort (CRIC) Study participantswho hadDoppler echocardiography performedwere considered for inclusion. PH was defined as the presence of estimated pulmonary artery systolic pressure (PASP) .35 mmHg and/or tricuspid regurgitant velocity (TRV).2.5 m/s. Associations between PH, PASP, and TRV and cardiovascular events, renal events, and all-cause mortality were examined using Cox proportional hazards models. Of 2959 eligible participants, 21% (n=625) had PH, with higher rates among those with lower levels of kidney function. In the multivariate model, older age, anemia, lower left ventricular ejection fraction, and presence of left ventricular hypertrophywere associated with greater odds of having PH.After adjusting for relevant confounDing variables, PH was independently associated with higher risk for death (hazard ratio, 1.38; 95% confidence interval, 1.10 to 1.72) and cardiovascular events (hazard ratio, 1.23; 95% confidence interval, 1.00 to 1.52) but not renal events. Similarly, TRV and PASP were associated with death and cardiovascular events but not renal events. In this study of patients with CKD and preserved left ventricular systolic function, we report a high prevalence of PH. PH and higher TRV and PASP (echocardiographicmeasures of PH) are associated with adverse outcomes inCKD. Future studies may explain the mechanisms that underlie these findings.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84959872481&origin=inward; http://dx.doi.org/10.1681/asn.2014111111; http://www.ncbi.nlm.nih.gov/pubmed/26386072; https://journals.lww.com/00001751-201603000-00024; http://www.jasn.org/cgi/doi/10.1681/ASN.2014111111; https://syndication.highwire.org/content/doi/10.1681/ASN.2014111111; https://hsrc.himmelfarb.gwu.edu/biostatscenter_facpubs/124; https://hsrc.himmelfarb.gwu.edu/cgi/viewcontent.cgi?article=1125&context=biostatscenter_facpubs; https://dx.doi.org/10.1681/asn.2014111111; https://journals.lww.com/jasn/fulltext/2016/03000/prevalence,_predictors,_and_outcomes_of_pulmonary.24.aspx; http://jasn.asnjournals.org/content/27/3/877; https://jasn.asnjournals.org/content/27/3/877; https://jasn.asnjournals.org/content/27/3/877.abstract; https://jasn.asnjournals.org/content/27/3/877.full.pdf; http://www.jasn.org/lookup/doi/10.1681/ASN.2014111111; https://jasn.asnjournals.org/content/jnephrol/27/3/877.full.pdf
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know